Mobocertinib: First Approval
Sign Up to like & getrecommendations! Published in 2021 at "Drugs"
DOI: 10.1007/s40265-021-01632-9
Abstract: Mobocertinib (EXKIVITY™) is a first-in-class EGFR tyrosine kinase inhibitor being developed for the treatment of EGFR exon 20 insertion (EGFRex20ins) -positive non-small cell lung cancer (NSCLC). Based on efficacy in patients whose disease had progressed… read more here.
Keywords: first approval; mobocertinib; mobocertinib first; approval ... See more keywords
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2023.2157815
Abstract: ABSTRACT Background Mobocertinib has demonstrated durable clinical benefit in platinum-pretreated patients (PPP) with epidermal growth factor receptor exon 20 insertion–positive non–small cell lung cancer (NSCLC). Research design and methods Pooled safety analysis of two studies… read more here.
Keywords: lung cancer; exon insertion; treatment; cancer ... See more keywords
Abstract 2781: De novo molecular mechanisms of resistance to mobocertinib
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Research"
DOI: 10.1158/1538-7445.am2022-2781
Abstract: Mobocertinib is an oral tyrosine kinase inhibitor recently approved by the FDA for the treatment of patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon… read more here.
Keywords: response; response mobocertinib; egfr exon; amplification ... See more keywords
Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-20-1683
Abstract: Most epidermal growth factor receptor (EGFR) exon 20 insertion (EGFRex20ins) driver mutations in non-small cell lung cancer (NSCLC) are insensitive to approved EGFR tyrosine kinase inhibitors (TKIs). To address the limitations of existing therapies targeting… read more here.
Keywords: cancer; exon insertion; egfr; egfr exon ... See more keywords
Targeting EGFR Exon 20 Insertion Mutation in Non–small cell Lung Cancer: Amivantamab and Mobocertinib
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Pharmacotherapy"
DOI: 10.1177/10600280221098398
Abstract: Objective To evaluate clinical data regarding the use of amivantamab and mobocertinib for epidermal growth factor receptor (EGFR) exon 20 insertion mutation non–small cell lung cancer (NSCLC) and assess their potential impact on the care… read more here.
Keywords: exon insertion; egfr exon; insertion mutation; amivantamab mobocertinib ... See more keywords
Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non–small cell lung cancer (mNSCLC): Treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2022.40.16_suppl.9099
Abstract: 9099 Background: Mobocertinib is a potent, irreversible, oral tyrosine kinase inhibitor selectively targeting EGFR ex20ins in NSCLC. Mobocertinib demonstrated clinical efficacy in 114 platinum-pretreated pts (PPP) with EGFR ex20ins+ mNSCLC in a phase 1/2 study.… read more here.
Keywords: brain metastases; platinum pretreated; brain; baseline brain ... See more keywords
Real-world efficacy and safety of mobocertinib in EGFR exon 20 insertion-mutated lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1010311
Abstract: Background Non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions (EGFRex20ins) is relatively resistant to the existing EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is a novel TKI that selectively targets EGFRex20ins and has demonstrated… read more here.
Keywords: lung cancer; brain; egfr exon; efficacy ... See more keywords
Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions
Sign Up to like & getrecommendations! Published in 2021 at "Biomedicines"
DOI: 10.3390/biomedicines9121938
Abstract: The majority of lung cancers are non-small-cell lung cancer (NSCLC) having a low survival rate. Recent studies have indicated the involvement of epidermal growth factor receptor (EGFR) oncogene mutations like EGFR exon 20 insertions (EGFRex20ins)… read more here.
Keywords: patent; egfr exon; mobocertinib; egfrex20ins mutation ... See more keywords